No, you should not start furosemide (Lasix) instead of Lokelma in this patient
In a patient on losartan 100 mg daily with hyperkalemia and no current diuretic use, you should initiate Lokelma (sodium zirconium cyclosilicate) to treat the hyperkalemia rather than starting furosemide for blood pressure control. This approach allows you to maintain or even optimize the losartan dose while managing the potassium elevation, rather than adding a diuretic that provides uncertain hyperkalemia benefit and may compromise your ability to use guideline-directed RAAS inhibitor therapy.
Why Lokelma is the Correct Choice
The primary issue here is hyperkalemia in a patient already on a RAAS inhibitor (losartan). According to the FDA label, Lokelma is specifically indicated for treatment of hyperkalemia in adults 1. The drug works rapidly, with significant potassium reductions observed within 1 hour of a single 10g dose, and maintains normokalemia with once-daily dosing 2.
The 2025 interdisciplinary recommendations emphasize that discontinuation or down-titration of RAAS inhibitor therapy should be discouraged, as these drugs improve outcomes in heart failure and proteinuric kidney disease 3. Lokelma enables you to maintain the losartan at its current dose (or potentially increase it if blood pressure remains elevated) while controlling the hyperkalemia.
Recent evidence demonstrates that sodium zirconium cyclosilicate is associated with improved maintenance and optimization of RAAS inhibitor therapy, with a 26% higher likelihood of maintaining RAAS inhibitors and 47% higher likelihood of up-titration 4. Multiple case series show that initiating SZC allowed patients to restart or up-titrate RAAS inhibitor therapy, with some achieving optimal medical therapy 5.
Why Furosemide is Not the Solution Here
While furosemide can lower blood pressure and does promote potassium excretion, using it as your primary strategy for hyperkalemia management in this context is problematic for several reasons:
1. Furosemide's Effect on Potassium is Unpredictable
Loop diuretics like furosemide actually cause potassium loss, which seems helpful initially. However, when combined with RAAS inhibitors, the net effect on potassium becomes unpredictable. The 2013 ACC/AHA Heart Failure guidelines note that diuretics can cause electrolyte depletion including hypokalemia, but this risk is "markedly enhanced when 2 diuretics are used in combination" 6.
In a patient already on losartan (which raises potassium), adding furosemide creates a precarious balance where you're simultaneously trying to raise and lower potassium through different mechanisms. One study showed that even with spironolactone 25-50mg plus furosemide 40mg plus an ARB, hyperkalemia (>5.5 mEq/L) still occurred in 8.8% of patients 7.
2. You're Not Addressing the Root Problem
The hyperkalemia is occurring because of the losartan, not because of volume overload or heart failure (which aren't mentioned in your scenario). Starting furosemide doesn't address why the potassium is elevated—it just adds another variable to an already complex electrolyte situation.
3. Furosemide May Force You to Reduce Losartan
If the hyperkalemia persists despite furosemide (which is likely), you'll be forced to reduce or discontinue the losartan 8. This is exactly what you want to avoid, as the 2025 recommendations explicitly state that "discontinuation of RAAS inhibitor therapies should be discouraged" 3.
4. Loop Diuretics Are Not First-Line for Hypertension
Loop diuretics are not recommended in current hypertension guidelines largely due to lack of outcome data 9. The 2017 EULAR gout guidelines actually suggest that "when gout occurs in a patient receiving loop or thiazide diuretics, substitute the diuretic if possible; for hypertension consider losartan or calcium channel blockers" 10. You're already on losartan—adding a loop diuretic for blood pressure control alone is not guideline-supported.
The Correct Management Algorithm
Step 1: Initiate Lokelma for Hyperkalemia
- Start Lokelma 10g three times daily for up to 48 hours for acute treatment 1
- Transition to maintenance dosing of 10g once daily
- Monitor potassium and adjust dose (range 5g every other day to 15g daily) 1
Step 2: Optimize Blood Pressure Control Once potassium is controlled with Lokelma:
- First option: Increase losartan dose if not at maximum (losartan can go up to 100mg daily, which you're already at, or consider switching to a different RAAS inhibitor at higher equivalent dose)
- Second option: Add a calcium channel blocker (amlodipine, etc.) for additional blood pressure control
- Third option: Add a thiazide-type diuretic (chlorthalidone or hydrochlorothiazide) if additional blood pressure lowering is needed, as these have better outcome data for hypertension than loop diuretics
Step 3: Monitor Closely
- Check potassium and creatinine 1-2 weeks after initiating Lokelma 1
- Reassess blood pressure response
- Adjust medications based on both parameters
Important Caveats
Watch for edema with Lokelma: Each 5g dose contains approximately 400mg of sodium. Monitor for signs of edema, particularly if the patient has heart failure or should restrict sodium intake 1. If edema develops, you can adjust dietary sodium or increase diuretics at that point—but this would be for volume management, not as primary hyperkalemia treatment.
Furosemide has a role—just not as first-line here: If your patient had both hyperkalemia and volume overload/heart failure with congestion, then furosemide would be indicated for the fluid retention 6, 11, 6. The 2022 AHA/ACC/HFSA guidelines state that "diuretics should be prescribed to patients who have evidence of congestion or fluid retention" 11. But treating hyperkalemia is not listed as an indication for diuretics in any major guideline.
Correct reversible factors: Before starting any new medication, ensure you've addressed reversible causes of hyperkalemia: dietary potassium intake, NSAIDs, potassium supplements, metabolic acidosis, constipation 3. The 2007 Canadian guidelines emphasize checking for "concomitant medications (eg, nonsteroidal anti-inflammatory drugs), hypovolemia, hypotension, urinary tract obstruction or infection" 8.